Bentham Science Logo

New Emirates Medical Journal

Volume 3, 2 Issues, 2022
ISSN: 0250-6882 (Online)
This journal supports open access

Track Your Manuscript:

Open Access Article

Repurposing Ruxolitinib in Combating COVID-19: A Mini-review

Inshia Begum1, Fathima Murthuza1, Juwairiya Syed Iqbaluddin1, Hafsah Fatima Arsal1, *
1 Department of Medical Education & Research, Dubai Health Authority, Al Riyadh St - Umm Hurair 2 Dubai, UAE



The pandemic caused by Coronavirus Disease 2019 (COVID-19), also known as Severe Acute Respiratory Syndrome-Related Coronavirus (SARS-CoV-2), is believed to be one of the greatest threats to global health in the 21st century. Recent collective evidence has warranted Ruxolitinib as a potential agent in recovery. Ruxolitinib is a potent and selective inhibitor of Jack kinase (JAK) 1 and 2 with modest to marked selectivity against tyrosine kinase 2 and JAK3, respectively.


The review aims to outline the current evidence regarding the repurposed treatment for COVID- 19 and to give an insight into the clinical trials. There has been considerable interest in introducing existing therapeutic agents against COVID-19 to reduce the severity of illness and ease the burden on public healthcare systems.


A literature search was conducted using keywords like ‘Ruxolitinib trial’ and ‘COVID-19 Ruxolitinib’ on PubMed, Google Scholar, Science Direct, and Cochrane databases to select research papers and articles on the topic published from January to October 2020. Inclusion criteria were restricted to articles on Ruxolitinib and COVID, whereas the exclusion criteria stipulated that any study done on COVID-19 involving mixed treatment regimen with Ruxolitinib and other drugs or any studies not pertinent to the purpose of the study were omitted.


Based on the successful outcomes of various researches conducted and clinical trials performed, the use of Ruxolitinib has shown significant improvement and faster clinical recovery among COVID-19 patients of varying severity of infection, advanced age and multiple comorbidities. This review provides an overview of various such studies with their promising outcomes.

Keywords: COVID-19, SARS-CoV-2, JAK1/2 inhibitors, Efficacy, Safety, Ruxolitinib, Coronavirus.

Article Information

Identifiers and Pagination:

Year: 2022
Volume: 3
Issue: 1
First Page: 42
Last Page: 46
Publisher Id: nemj-3-42
DOI: 10.2174/0250688202666210715141439

Article History:

Received Date: 02/2/2021
Revision Received Date: 09/6/2021
Acceptance Date: 15/6/2021
Electronic publication date: 21/01/2022
Collection year: 2022

© 2022 Begum et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at Department of Medical Education & Research, Dubai Health Authority, Al Riyadh St - Umm Hurair 2 Dubai, UAE; Tel: 04 219 1920; E-mail:


Abdullah Shehab
Emirates Cardiac Society
Emirates Medical Association
(United Arab Emirates)
View Full Editorial Board

Annual Journal Metrics


Acceptance rate = 40%

Average review speed: 45 days average

18 days from acceptance to publication